Physician profile
Jihad Khattab
NPI 1730126111
$2,188.33
in general payments reported to CMS, 2019-2025
24 companies · $677 in 2025
The $677 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.98 · 2020: $194 · 2021: $56.71 · 2022: $186 · 2023: $367 · 2024: $675 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.62 |
| Education | $241.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $459.11 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $400.59 | 2021-2025 | |
| Abbvie INC. | $297.26 | 2023-2025 | |
| Celgene Corporation | $257.72 | 2021-2025 | Reblozyl, Breyanzi |
| Beigene USA, INC. | $125.37 | 2023-2024 | Brukinsa |
| Seagen INC. | $99.00 | 2020 | |
| Astellas Pharma US INC | $95.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $49.50 | 2021-2025 | Reblozyl, Opdivo |
| Glaxosmithkline, LLC. | $42.73 | 2025 | Zejula, Jemperli |
| Beone Medicines USA, INC. | $38.99 | 2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $32.46 | 2024 | Onivyde, Tazverik |
| Sun Pharmaceutical Industries INC. | $31.78 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.51 | 2022-2025 | Ninlaro |
| Gilead Sciences, INC. | $27.64 | 2021-2025 | Trodelvy |
| Acrotech Biopharma INC. | $25.90 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $23.93 | 2022 | |
| Daiichi Sankyo INC. | $22.66 | 2025 | Enhertu |
| Recordati_rare_diseases_inc. | $22.63 | 2025 | Enjaymo |
| Sobi, INC | $20.65 | 2022 | |
| Janssen Biotech, INC. | $18.84 | 2024 | Carvykti, Tecvayli, Talvey |
| Genentech USA, INC. | $17.70 | 2019 | |
| Genzyme Corporation | $17.24 | 2023 | |
| Taiho Oncology, INC. | $15.84 | 2022 | |
| Clovis Oncology, INC. | $15.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jihad Khattab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.